What Is the NMPA Priority Review Pathway and How Does It Speed Up Drug Approvals in China?

A comprehensive guide to China’s priority drug review mechanism and how foreign biotech companies can leverage it for accelerated market access.

Introduction

China’s NMPA priority review pathway is one of the most powerful tools available to foreign biotech companies seeking faster access to the Chinese pharmaceutical market. Established in its current form under the 2020 Measures for Drug Registration and refined through subsequent NMPA announcements, the priority review mechanism provides significantly accelerated review timelines for drugs that address serious or life-threatening conditions, rare diseases, pediatric indications, or urgent public health needs. Since its implementation, priority review has reduced NMPA drug approval times by 40–60% compared to standard review. This article explains what the NMPA priority review pathway is, how it works, who qualifies, and how foreign biotech companies can successfully leverage it for their products.

The Regulatory Basis of Priority Review

The NMPA priority review pathway was formally established under Article 68 of the 2020 Measures for Drug Registration, which replaced the earlier 2016 priority review pilot program. The legal framework has been further elaborated through several complementary mechanisms:

• Drug Administration Law (2019 revision): Articles 16 and 27 establish the legal basis for priority review and conditional approval of urgently needed drugs.
• Measures for Drug Registration (2020): Articles 68–76 provide detailed provisions on priority review scope, application procedures, and review timelines.
• NMPA Announcement No. 44 (2024): The most recent update to priority review criteria, expanding eligibility for pediatric drugs and innovative biologics.
• CDE Guidelines on Priority Review Application (2023): Procedural guidance on preparing and submitting priority review applications to CDE.

The priority review pathway is integrated with other accelerated approval mechanisms including Breakthrough Therapy Designation (BTD) and Conditional Approval, and companies can apply for multiple mechanisms simultaneously.

Eligibility Criteria: Which Drugs Qualify for Priority Review?

The NMPA has defined six categories of drugs eligible for priority review. Foreign biotech companies should carefully assess whether their products meet one or more of the following criteria:

• Drugs for serious or life-threatening diseases with no effective treatment in China: This is the broadest and most commonly used category. Drugs targeting cancer, rare diseases, neurodegenerative disorders, cardiovascular emergencies, and infectious diseases with high mortality typically qualify. The key requirement is that the drug offers a meaningful therapeutic advantage over existing treatments or addresses an unmet medical need.
• Drugs for diseases that are rare in China: Drugs designated as orphan drugs for rare diseases (defined as affecting fewer than 1 in 10,000 people in China, or with a prevalence of less than 600,000 patients) are eligible for priority review. The NMPA maintains a list of approved rare disease designations.
• Pediatric drugs: New drugs for pediatric indications, particularly those with appropriate pediatric formulations, qualify for priority review. This category was expanded in the 2024 NMPA guidelines to include drugs that address serious pediatric conditions.
• Drugs for public health emergencies: Drugs needed for outbreak prevention or treatment (infectious diseases, epidemics) qualify automatically. This category was extensively used during the COVID-19 pandemic for vaccines and therapeutics.
• Innovative drugs with breakthrough therapy designation: Drugs that receive CDE’s Breakthrough Therapy Designation are automatically eligible for priority review at the NDA stage.
• Drugs for specific national health priorities: Certain drug categories may be designated by the NMPA as national health priorities, including drugs for antimicrobial resistance, mental health, substance abuse treatment, and geriatric conditions.

The Application Process: Step by Step

Applying for NMPA priority review involves a structured process that should begin well before the formal NDA submission:

1. Pre-submission consultation (recommended, 3–6 months before NDA): Foreign companies should request a pre-submission consultation meeting with CDE to discuss priority review eligibility. The CDE will review the drug’s clinical data package, the target indication’s unmet medical need, and the drug’s potential therapeutic advantage. This consultation is not mandatory but is highly recommended as it allows the company to address any data gaps before formal application.
2. Priority review application submission (with NDA or after IND): The priority review application is submitted to CDE using the prescribed form (Annex 2 of the CDE guidelines). For drugs already in clinical development, the application can be submitted after Phase II results that demonstrate promising efficacy. For drugs completing Phase III, the application is typically bundled with the NDA submission.
3. CDE review and decision (45 working days): The CDE has 45 working days (about 2 calendar months) to review the priority review application and issue a decision. The CDE considers the strength of the clinical evidence, the seriousness of the condition, the availability of alternative treatments in China, and the drug’s potential public health impact.
4. Inclusion in priority review list: Approved applications are publicly listed on the CDE’s priority review list, which is updated monthly. The listing triggers the accelerated review timeline and provides CDE with additional resources for the review.

Timeline Benefits: How Much Faster Is Priority Review?

The primary benefit of priority review is a dramatically shortened NMPA review timeline. Under current regulations:

• Standard NDA review timeline (chemical drugs): 120 working days for technical review (plus clock stops for information requests). Total: 12–18 months typically.
• Priority review timeline (chemical drugs): 80 working days for technical review. Total: 6–9 months typically.
• Standard NDA review timeline (biologics): 200 working days for technical review. Total: 12–18 months typically.
• Priority review timeline (biologics): 120 working days for technical review. Total: 9–12 months typically.

In practice, the total time savings are even greater because priority review also involves:

• Faster scheduling of CDE review meetings: Priority review drugs receive expedited scheduling for CDE advisory committee meetings.
• Shorter clock-stop periods: CDE commits to reviewing applicant responses to information requests within 30 working days instead of 60 working days for standard review.
• Rolling submission: Priority review applicants can submit completed modules of the NDA dossier on a rolling basis, allowing CDE to start reviewing available modules while the applicant completes the remaining modules — potentially saving an additional 2–4 months.
• Priority for on-site inspection scheduling: Manufacturing facility inspections and sample testing are prioritized for drugs in the priority review pathway.

Priority Review vs. Other Accelerated Pathways

Foreign biotech companies should understand how priority review relates to and complements other accelerated pathways offered by the NMPA and CDE:

• Breakthrough Therapy Designation (BTD): BTD focuses on the clinical development phase, providing intensive CDE guidance on trial design and potentially enabling smaller or shorter pivotal trials. BTD automatically qualifies a drug for priority review at the NDA stage. Priority review focuses on the review phase only.
• Conditional Approval: Conditional approval allows early market access based on surrogate endpoints, with mandatory post-marketing confirmatory studies. Conditional approval and priority review can be applied in parallel — a drug may receive conditional approval through priority review for the fastest possible market access.
• Special Review for Innovative Drugs: The CDE’s special review mechanism (for Class 1 innovative drugs) provides enhanced communication with reviewers and can be combined with priority review for maximum acceleration.
• Emergency Use Authorization (EUA): For public health emergencies, the NMPA can issue EUAs separately from the priority review pathway. EUAs are temporary and require conversion to full approval within a specified timeframe.

Real-World Outcomes: Priority Review Approval Statistics

Based on publicly available CDE data for 2022–2025, the following patterns have emerged for priority review approvals:

• Total priority review applications received: Approximately 300–400 per year across all drug categories.
• Approval rate for priority review requests: 65–75% of applications are approved for inclusion in the priority review list.
• Drugs approved through priority review: Approximately 150–200 drugs receive NMPA approval through the priority review pathway annually, representing 20–25% of all new drug approvals.
• Average time from priority review listing to NMPA approval: 8–14 months for chemical drugs and 12–18 months for biologics (compared to 14–24 months and 18–30 months respectively for standard review).
• Most common indications approved through priority review: Oncology (45%), rare diseases (20%), cardiovascular (10%), infectious diseases (10%), pediatrics (5%), and others (10%).

Foreign-invested companies and their Chinese subsidiaries account for approximately 30–35% of priority review approvals, reflecting consistent usage of this pathway by multinational pharmaceutical companies.

Strategic Considerations for Foreign Biotech Companies

To maximize the chances of obtaining and benefiting from NMPA priority review, foreign biotech companies should consider the following strategies:

1. Align China development with global timelines: Submit the priority review application as early as possible — ideally when promising Phase II data is available, rather than waiting for Phase III completion.
2. Build a strong unmet-need case: The priority review application must convincingly demonstrate that the target disease has no effective treatment available in China, or that the drug offers a significant improvement over existing therapies. Comparative data against standard of care in China is particularly valuable.
3. Generate China-specific data: While the NMPA accepts foreign clinical data under ICH E5 and E17, having China-specific clinical data from bridging studies or Chinese patient subsets significantly strengthens the priority review case.
4. Engage CDE early and often: Pre-submission consultation meetings, BTD applications (if eligible), and ongoing communication with CDE reviewers throughout the review process are strongly associated with successful priority review outcomes.
5. Prepare for expedited manufacturing inspection: Since priority review compresses the overall timeline, foreign companies must ensure their manufacturing facilities and supply chains are inspection-ready well before the expected priority review decision.
6. Plan for accelerated launch: With a priority review timeline of 6–12 months, commercial launch preparations (pricing, reimbursement applications, market access strategies, distribution network) should begin in parallel with the NDA submission, not after approval.

Conclusion

The NMPA priority review pathway is a powerful mechanism that can reduce drug approval timelines in China by 40–60%, bringing innovative therapies to Chinese patients significantly faster than the standard review process. For foreign biotech companies, successful navigation of the priority review pathway requires early engagement with CDE, careful preparation of the eligibility case, strategic alignment of China and global development plans, and disciplined preparation for accelerated manufacturing and commercial launch timelines. When combined with other accelerated mechanisms such as Breakthrough Therapy Designation and Conditional Approval, priority review can enable foreign biotech companies to bring their drugs to the Chinese market in as little as 6–12 months from NDA submission — a dramatic improvement over the 2–3 year timelines that were standard just a decade ago.

This article is for informational purposes only and does not constitute legal or regulatory advice. Priority review eligibility criteria, application procedures, and timelines are based on current NMPA and CDE regulations as of 2025–2026 and may be subject to change. Foreign companies should consult qualified regulatory affairs professionals for advice on their specific drug products and circumstances.